Telix Pharmaceuticals Limited
ACN 616 620 369
Suite 401, 55 Flemington Road
North Melbourne
Victoria, 3051
Australia

Investor Conference Call

Melbourne (Australia) – 30th November 2020. Telix Pharmaceuticals Limited (ASX: TLX, 'Telix', the 'Company') advises it will hold an investor conference call at 8:00am AEDT on Tuesday 1st December to provide further detail in relation to Telix's acquisition of TheraPharm GmbH.

Participants can register for the conference call by navigating to:

https://s1.c-conf.com/DiamondPass/10011242-dT78g6.html

Please note that registered participants will receive their dial in number upon registration.

About Telix Pharmaceuticals Limited

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical needs in prostate, kidney and brain cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.

Telix Corporate Contact
Dr. Christian Behrenbruch
Telix Pharmaceuticals Limited
CEO
Email: chris@telixpharma.com

Telix Investor Relations
Dr. David N. Cade
Telix Pharmaceuticals Limited
CBO and Head of Investor Relations
Email: david.cade@telixpharma.com